Beyond Air, Inc. (XAIR)

NASDAQ: XAIR · Real-Time Price · USD
0.1790
+0.0012 (0.67%)
At close: Jul 3, 2025, 1:00 PM
0.1781
-0.0009 (-0.50%)
After-hours: Jul 3, 2025, 4:57 PM EDT
0.67%
Market Cap 16.61M
Revenue (ttm) 3.71M
Net Income (ttm) -46.63M
Shares Out 92.79M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 702,165
Open 0.1800
Previous Close 0.1778
Day's Range 0.1758 - 0.1850
52-Week Range 0.1521 - 0.6761
Beta 0.23
Analysts Buy
Price Target 1.50 (+737.99%)
Earnings Date Jun 17, 2025

About XAIR

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2011
Employees 61
Stock Exchange NASDAQ
Ticker Symbol XAIR
Full Company Profile

Financial Performance

In 2024, Beyond Air's revenue was $3.71 million, an increase of 219.67% compared to the previous year's $1.16 million. Losses were -$46.63 million, -22.60% less than in 2023.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price target is $1.5, which is an increase of 737.99% from the latest price.

Price Target
$1.5
(737.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Conference Call June 17, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - CFO, Principal Financial Officer & Principal Accounting Officer ...

16 days ago - Seeking Alpha

Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know

Beyond Air, Inc. XAIR released its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures from the quarter.

16 days ago - Benzinga

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and int...

16 days ago - GlobeNewsWire

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

LungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the count...

17 days ago - GlobeNewsWire

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Beyond Air, Inc. XAIR will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.

17 days ago - Benzinga

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessi...

6 weeks ago - GlobeNewsWire

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder

2 months ago - GlobeNewsWire

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease Professor Shechtman joins f...

2 months ago - GlobeNewsWire

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnes...

3 months ago - GlobeNewsWire

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO techno...

3 months ago - GlobeNewsWire

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation devel...

3 months ago - GlobeNewsWire

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH syst...

4 months ago - GlobeNewsWire

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...

4 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Exe...

5 months ago - Seeking Alpha

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH ® in Europe and Market Authorization in Australia; internation...

5 months ago - GlobeNewsWire

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...

5 months ago - GlobeNewsWire

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...

5 months ago - GlobeNewsWire

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...

5 months ago - GlobeNewsWire

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative ...

7 months ago - GlobeNewsWire

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for soli...

7 months ago - GlobeNewsWire

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery

7 months ago - GlobeNewsWire

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders Professor Kornberg will assist in accelerating th...

7 months ago - GlobeNewsWire

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...

8 months ago - GlobeNewsWire

Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR) Q2 2025 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Ex...

8 months ago - Seeking Alpha

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private...

8 months ago - GlobeNewsWire